AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17394176 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 402
Study 16121879 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL bupivacaine 0.25% intraperitoneal spray
Number of subjects: 100
Study 16121879 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL bupivacaine 0.25% intraperitoneal spray mixed with 200 mg ketoprofen
Number of subjects: 100
Study 16121879 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL bupivacaine 0.25% intraperitoneal spray and intravenous 200 mg ketoprofen
Number of subjects: 100
Study 16121879 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ketoprofen intravenously
Number of subjects: 100
Study 16121879 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 11876691 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose azathioprine (< 2 mg/kg)
Number of subjects: 113
Study 11876691 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 113
Study 10438404 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone (100 mg x 2/day)
Number of subjects: 64
Study 10438404 — intervention group
Group type: COMPARATOR
Intervention: Oral micronized progesterone (200 mg x 4/day)
Number of subjects: 64
Study 8566939 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteers searching for RCTs
Number of subjects: 3
Study 1637021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil, 500 mg twice daily for 20 days
Number of subjects: 123
Study 1637021 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline, 100 mg three times daily for 20 days
Number of subjects: 123
Study 1637021 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 123
Study 1637021 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 123
Study 6383111 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometrine 0.25 mg
Number of subjects: 0
Study 6383111 — intervention group
Group type: EXPERIMENTAL
Intervention: Syntocinon 10 mg
Number of subjects: 0
Study 6383111 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study 31498136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention rehabilitation unit (IU) with naturalistic lighting (artificial sunlight spectrum)
Number of subjects: 90
Study 31498136 — intervention group
Group type: COMPARATOR
Intervention: Control rehabilitation unit (CU) with standard indoor lighting
Number of subjects: 90
Study 29305451 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscal allograft transplantation
Number of subjects: 36
Study 29305451 — intervention group
Group type: COMPARATOR
Intervention: Personalized physiotherapy
Number of subjects: 36
Study 25844756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg
Number of subjects: 485
Study 25844756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80-120 mg
Number of subjects: 485
Study 25844756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 25844756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 485
Study 23228988 — intervention group
Group type: COMPARATOR
Intervention: ACNU alone
Number of subjects: 310
Study 23228988 — intervention group
Group type: EXPERIMENTAL
Intervention: ACNU + PCZ
Number of subjects: 310
Study 23228988 — intervention group
Group type: COMPARATOR
Intervention: ACNU alone (GBM subgroup)
Number of subjects: 310
Study 23228988 — intervention group
Group type: EXPERIMENTAL
Intervention: ACNU + PCZ (GBM subgroup)
Number of subjects: 310
Study 23228988 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 310
Study 21515398 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan (3 g/d)
Number of subjects: 33
Study 21515398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 19112336 — intervention group
Group type: EXPERIMENTAL
Intervention: Limaprost (15 microg/d)
Number of subjects: 79
Study 19112336 — intervention group
Group type: COMPARATOR
Intervention: Etodolac (400 mg/d)
Number of subjects: 79
Study 16014819 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and nutrition treatment (nutrition counseling and child behavioral management training for parents)
Number of subjects: 1
Study 15574145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron therapy
Number of subjects: 0
Study 15574145 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 0
Study 11789748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hormone replacement
Number of subjects: 72
Study 11789748 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement
Number of subjects: 72
Study 9384464 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) 2 ng kg(‐1) min(‐1)
Number of subjects: 13
Study 9384464 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) 4 ng kg(‐1) min(‐1)
Number of subjects: 13
Study 9384464 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) 8 ng kg(‐1) min(‐1)
Number of subjects: 13
Study 9384464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1314337 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxamine (intravenous administration)
Number of subjects: 0
Study 1314337 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE, intravenous administration)
Number of subjects: 0
Study 3908131 — intervention group
Group type: EXPERIMENTAL
Intervention: iodopropylidene glycerol (IPG-Organidin), two tablets four times daily
Number of subjects: 15
Study 3908131 — intervention group
Group type: EXPERIMENTAL
Intervention: iodopropylidene glycerol (IPG-Organidin)
Number of subjects: 15
Study 3908131 — intervention group
Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 15
Study 30620140 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative topical anti-inflammatory medication with a combination of prednisolone acetate (10 mg/ml) and nepafenac (1 mg/ml)
Number of subjects: 103
Study 30620140 — intervention group
Group type: COMPARATOR
Intervention: No preoperative anti-inflammatory treatment
Number of subjects: 103
Study 30620140 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative topical anti-inflammatory medication with a combination of prednisolone acetate and nepafenac
Number of subjects: 103
Study 29652778 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck Stabilization Exercises (NSE)
Number of subjects: 81
Study 29652778 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) and Neck Stabilization Exercises (NSE)
Number of subjects: 81
Study 29652778 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential Current (IFC) and Neck Stabilization Exercises (NSE)
Number of subjects: 81
Study 29652778 — intervention group
Group type: COMPARATOR
Intervention: Control group (NSE only)
Number of subjects: 81
Study 27171319 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor health information workshop (2-hour duration)
Number of subjects: 40
Study 25064627 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (T&A)
Number of subjects: 80
Study 25064627 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 80
Study 22971487 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg orally once daily
Number of subjects: 586
Study 22971487 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg orally twice daily
Number of subjects: 586
Study 22971487 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 586
Study 22971487 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 586
Study 20200972 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 22
Study 20200972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19087678 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus continuous renal replacement therapy (CRRT)
Number of subjects: 40
Study 19087678 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 40
Study 16238122 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g of xanthan gum with test meal (ham sandwich - 90 kcal)
Number of subjects: 21
Study 16238122 — intervention group
Group type: COMPARATOR
Intervention: Placebo with test meal (ham sandwich - 90 kcal)
Number of subjects: 21
Study 12236643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevel
Number of subjects: 45
Study 12236643 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamfer
Number of subjects: 45
Study 12236643 — intervention group
Group type: EXPERIMENTAL
Intervention: Butt joint
Number of subjects: 45
Study 9952140 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 100
Study 9952140 — intervention group
Group type: COMPARATOR
Intervention: Air therapy (control)
Number of subjects: 100
Study 7749825 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 60 IU/d
Number of subjects: 8
Study 7749825 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 200 IU/d
Number of subjects: 8
Study 7749825 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 400 IU/d
Number of subjects: 8
Study 7749825 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 800 IU/d
Number of subjects: 8
Study 7749825 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 1200 IU/d
Number of subjects: 8
Study 7749825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1971660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine or Pravastatin treatment
Number of subjects: 47
Study 1971660 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ischaemic heart disease (n=48)
Number of subjects: 47
Study 1971660 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age and sex)
Number of subjects: 47
Study 393078 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 50
Study 393078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30048324 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose contrast enhanced CT
Number of subjects: 60
Study 30048324 — intervention group
Group type: COMPARATOR
Intervention: Standard CT
Number of subjects: 60
Study 30523055 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin, mitoxantrone, or idarubicin in addition to standard-dose cytarabine and etoposide for induction chemotherapy
Number of subjects: 188
Study 30523055 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose cytarabine or high-dose cytarabine induction, both with daunorubicin and etoposide
Number of subjects: 188
Study 30523055 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-identical related donor availability
Number of subjects: 188
Study 28940815 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg, pantoprazole 40 mg twice daily for 10 days)
Number of subjects: 478
Study 28940815 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (amoxicillin 1000 mg with pantoprazole 40 mg twice daily for 5 days, followed by clarithromycin 500 mg with metronidazole 500 mg and pantoprazole 40 mg twice daily for 5 days)
Number of subjects: 478
Study 28940815 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy in clarithromycin-resistant strains
Number of subjects: 478
Study 28940815 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy in clarithromycin-resistant strains
Number of subjects: 478
Study 26114582 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch-screen version of health status questionnaires (HSQs)
Number of subjects: 20
Study 26114582 — intervention group
Group type: COMPARATOR
Intervention: Paper version of health status questionnaires (HSQs)
Number of subjects: 20
Study 22868243 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine 1250 mg/m² twice daily on days 1‐14 (Arm A)
Number of subjects: 80
Study 22868243 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 1000 mg/m² twice daily on days 1‐14, oxaliplatin 100 mg/m² on day 1 initially, 130 mg/m² for subsequent cycles (Arm B)
Number of subjects: 80
Study 20955744 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term counselling
Number of subjects: 49
Study 20955744 — intervention group
Group type: COMPARATOR
Intervention: Intensive counselling
Number of subjects: 49
Study 20955744 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restraint
Number of subjects: 49
Study 19053049 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times a day) with a 1,400 Kcal/day diet plus vitamin E (800 IU) daily
Number of subjects: 50
Study 19053049 — intervention group
Group type: COMPARATOR
Intervention: Diet plus vitamin E (800 IU) daily
Number of subjects: 50
Study 19053049 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss >= 5%
Number of subjects: 50
Study 19053049 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss >= 9%
Number of subjects: 50
Study 17041248 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE program (Creating Opportunities for Parent Empowerment)
Number of subjects: 143
Study 17041248 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 143
Study 15069395 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula
Number of subjects: 238
Study 11157603 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin, 400 mg/d for 10 days
Number of subjects: 411
Study 11157603 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin, 1,000 mg tid for 10 days
Number of subjects: 411
Study 11157603 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 411
Study 11157603 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 411
Study 9593156 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1 g/8 h)
Number of subjects: 79
Study 9593156 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g/8 h) plus Gentamicin (4 mg/kg daily)
Number of subjects: 79
Study 9593156 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 79
Study 9593156 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime plus Gentamicin
Number of subjects: 79
Study 7921936 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Needle Suspension (MNS)
Number of subjects: 50
Study 7921936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagina/Obturator Shelf (VOS)
Number of subjects: 50
Study 2848900 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of oral acyclovir, twice daily for one year
Number of subjects: 33
Study 2848900 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for one year
Number of subjects: 33
Study 29636004 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous administration of sufentanil (group CV)
Number of subjects: 102
Study 29636004 — intervention group
Group type: COMPARATOR
Intervention: Peripheral venous administration of sufentanil (group PV)
Number of subjects: 102
Study 29636004 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CV and PV)
Number of subjects: 102
Study 28543352 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg
Number of subjects: 17
Study 28543352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 26628268 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered six-lesson 10-week cognitive behavioural therapy (iCBT) intervention for PTSD
Number of subjects: 72
Study 26628268 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 72
Study 23987791 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus standard antiemetic therapy (ondansetron plus dexamethasone)
Number of subjects: 0
Study 23987791 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic therapy alone
Number of subjects: 0
Study 18771232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose-lowering therapy (HbA1c < 6%) in ACCORD trial
Number of subjects: 0
Study 18771232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose-lowering therapy (HbA1c ≤ 6.5%, modified release gliclazide as main treatment) in ADVANCE trial
Number of subjects: 0
Study 18771232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose-lowering therapy in VA-Diabetes trial
Number of subjects: 0
Study 18771232 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control in ACCORD, ADVANCE, and VA-Diabetes trials
Number of subjects: 0
Study 15705991 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled colistin (75 mg in 4 mL saline solution)
Number of subjects: 20
Study 15705991 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 20
Study 15705991 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled colistin
Number of subjects: 20
Study 15705991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12851547 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 66
Study 12851547 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin E)
Number of subjects: 66
Study 10564839 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized ABT-431 (5 mg); C(max) was 13.3±0.9 ng/ml and AUC(0-24) was 33.2±10.6 h ng/ml in dogs.
Number of subjects: 0
Study 10564839 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral inhalation of ABT-431 (dosage levels between 3.3 and 13.2 mg); demonstrated rapid absorption and dose-dependent increase in AUC.
Number of subjects: 0
Study 8708961 — intervention group
Group type: EXPERIMENTAL
Intervention: Single instrumentation (Group A)
Number of subjects: 15
Study 8708961 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple instrumentations (Group B)
Number of subjects: 15
Study 8708961 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 15
Study 1746653 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education, HIV antibody test, and test results
Number of subjects: 186
Study 1746653 — intervention group
Group type: COMPARATOR
Intervention: AIDS education alone
Number of subjects: 186
Study 6269770 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy with VP‐16‐213, vincristine (Oncovin), cyclophosphamide, and Adriamycin (VOCA)
Number of subjects: 62
Study 6269770 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with VP‐16‐213, vincristine (Oncovin), cyclophosphamide, Adriamycin (VOCA) plus low-dose (40 mg/m2) cisplatin (VOCAP)
Number of subjects: 62
Study 30032394 — intervention group
Group type: EXPERIMENTAL
Intervention: SST (Social Skills Training)
Number of subjects: 122
Study 30032394 — intervention group
Group type: EXPERIMENTAL
Intervention: SST-PTI (Social Skills Training with Parent and Teacher Involvement)
Number of subjects: 122
Study 30032394 — intervention group
Group type: EXPERIMENTAL
Intervention: SST
Number of subjects: 122
Study 30032394 — intervention group
Group type: EXPERIMENTAL
Intervention: SST-PTI
Number of subjects: 122
Study 27294349 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit Juice (GFJ)
Number of subjects: 12
Study 27294349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice (PJ)
Number of subjects: 12
Study 27294349 — intervention group
Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 12
Study 25918277 — intervention group
Group type: EXPERIMENTAL
Intervention: PediQUEST Memorial Symptom Assessment Scale (PQ‐MSAS) administered 920 times
Number of subjects: 104
Study 25918277 — intervention group
Group type: EXPERIMENTAL
Intervention: PediQUEST Memorial Symptom Assessment Scale (PQ‐MSAS) in the last 12 weeks of life
Number of subjects: 104
Study 25918277 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cancer‐directed therapy in the final 12 weeks of life
Number of subjects: 104
Study 23602942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) program, 12 sessions
Number of subjects: 145
Study 21347803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 3 mg once daily for 52 weeks
Number of subjects: 123
Study 21347803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 19081190 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical high concentration (10%) capsaicin
Number of subjects: 39
Study 19081190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of three GCH1 SNPs
Number of subjects: 39
Study 16806618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low back pain group (N=26)
Number of subjects: 50
Study 16806618 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (N=24)
Number of subjects: 50
Study 15242361 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg
Number of subjects: 283
Study 15242361 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 283
Study 15242361 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 283
Study 15242361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 15242361 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (all doses)
Number of subjects: 283
Study 11224865 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous intradiscal radiofrequency thermocoagulation (90 seconds, 70 C lesion)
Number of subjects: 28
Study 11224865 — intervention group
Group type: COMPARATOR
Intervention: Control group (same procedure without radiofrequency current)
Number of subjects: 28
Study 9412546 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunostimulant (OM-85 BV)
Number of subjects: 381
Study 9412546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study 8510708 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled heparin (1000 U per kilogram)
Number of subjects: 12
Study 8510708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (20 mg)
Number of subjects: 12
Study 8510708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12